4.4 Review

Estrogen and progesterone receptors in breast cancer

Journal

FUTURE ONCOLOGY
Volume 10, Issue 14, Pages 2293-2301

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.110

Keywords

breast cancer; estrogen receptor; progesterone receptor

Categories

Funding

  1. Ministry of Higher Education, Malaysia [UM.C/HlR/MOHE/06]

Ask authors/readers for more resources

Breast cancer is the most common cancer in women worldwide. The majority of breast cancers show overexpression of estrogen receptors (ERs) and progesterone receptors (PRs). The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers. Since information about ER and PR is vital for patient management, quality assurance is important to ensure accurate testing. In recent guidelines, the recommended definition of ER and PR positivity is 1% or more of cells that stain positive. Semiquantitative assessment of ER and PR is important for prognosis and, hence, management. Even with the development of genomic tests, hormone receptor status remains the most significant predictive and prognostic biomarker.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available